Contact Us

DESTINATION NEWS

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

May 30, 2024

SUZHOU,ChinaandROCKVILLE,Md.,May 24,2024-- Ascentage Pharma (6855.HK),a global biopharmaceutical company engaged in developing novel therapies for cancer,chronic hepatitis B (CHB),and age-related dis

Antengene To Present One Oral and Four Abstracts at ASCO 2024

May 30, 2024

Oral Presentation:a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer

URBAN SPORTS AND STREET ARTS MEET IN SINGAPORE AS PART OF A GLOBAL WARM-UP TO THE PARIS 2024 OLYMPIC GAMES

May 30, 2024

The unique event,which is among the first global events created to build excitement for the upcoming Olympic Games,sees French andSingaporeans athletes and artists coming together to revitalise the ic

Friso Launches #MovetoGoodPoop Movement to Champion Good Gut Health in Children with Music and Storytelling

May 30, 2024

Homegrown singer-songwriter-producer Derrick Hoh announced as Friso Brand Ambassador for 2024/25 SINGAPORE,May 24,2024--Friso,a leading nutrition formula milk brand with over 150 years of Dutch dairy

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

May 30, 2024

Antitumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA.

Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor

May 30, 2024

SHANGHAI,May 24,2024--Tyligand Bioscience,a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies,announced that the first patient had been dosed

1 ... 330 331 332 333 334 335 336 ... 346